BLU-5937, A Potent and Selective P2X3 Antagonist, For the Treatment of Chronic Itch: Evidence from Pre-Clinical Studies

被引：1
|
作者：
Chauret, N. [1 ]
Ase, A. R. [2 ]
Seguela, P. [2 ]
Liu, X. Y. [3 ]
Matzouranis, T. [1 ]
Garceau, D. [1 ]
机构：
[1] Bellus Hlth Inc, Laval, PQ, Canada
[2] Mc Gill, MNI, Montreal, PQ, Canada
[3] Univ Washington, St Louis, MO USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 09期
关键词：
D O I：
10.1016/j.jid.2019.07.110
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
106
引用
收藏
页码：S232 / S232
页数：1
相关论文
共 50 条
  • [31] Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist
    McGarvey, Lorcan
    Smith, Jaclyn
    Birring, Surinder
    Morice, Alyn
    Sher, Mandel
    Wu, Wen-Chi
    Muccino, David
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [32] The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough.
    Smith, Jaclyn
    Mcgarvey, Lorcan P.
    Morice, Alyn H.
    Birring, Surinder S.
    Kitt, Michael M.
    Sher, Mandel R.
    Tershakovec, Andrew M.
    Wu, Wen-Chi
    Xu, Zhi Jin
    Muccino, David R.
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [33] Pharmadynamic (PD) & pharmacokinetic (PK) properties of AF-219: first in class, selective, clinical P2X3 antagonist in development for chronic pain and related conditions
    Ford, Anthony P.
    Smith, Steven A.
    Dillon, Michael P.
    FASEB JOURNAL, 2013, 27
  • [34] A First-In-Human study of HS-10383, a Selective P2X3 Receptor Antagonist for the treatment of Refractory or Unexplained Chronic Cough, in Healthy Chinese Subjects
    Li, Qian
    Chen, Ke-Guang
    Zhang, Ye-Hui
    Zhou, Hai-Yan
    Ye, Pan-Pan
    Song, Lin-Lin
    Zhao, Fu-Rong
    Shi, Jin-Yi
    Wu, Qiong
    Yu, Xiang-Qing
    Pan, Chao
    Yuan, Dong
    Xu, Miao
    Xing, Aiping
    Yang, Xin-Mei
    Zhao, Wei
    RESPIROLOGY, 2023, 28 : 60 - 61
  • [35] Characteristics of a Chronic Cough Population Participating in Two Large Phase III Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist
    Dicpinigaitis, P.
    McGarvey, L.
    Morice, A. H.
    Smith, J.
    Birring, S. S.
    Pavord, I. D.
    Iskold, B.
    Tzontcheva, A.
    Li, Q.
    La Rosa, C.
    Muccino, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [36] Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough
    Gupta, Pranav
    Hussain, Azher
    Ford, Anthony P.
    Smith, Steven
    Nussbaum, Jesse C.
    Stoch, Aubrey
    Iwamoto, Marian
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1054 - 1067
  • [37] BENEFITS OBSERVED WITH PATIENT-REPORTED OUTCOMES IN A PHASE 2B CLINICAL TRIAL OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN CHRONIC COUGH
    Birring, S. S.
    McGarvey, L. P.
    Smith, J. A.
    Morice, A. H.
    Sher, M. R.
    Schelfhout, J.
    Mehta, A.
    Muccino, D. R.
    THORAX, 2019, 74 : A18 - A19
  • [38] BENEFITS OBSERVED WITH PATIENT-REPORTED OUTCOMES IN A PHASE 2B CLINICAL TRIAL OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST IN CHRONIC COUGH
    Mehta, Anish
    Birring, Surinder
    McGarvey, Lorcan
    Smith, Jacky
    Morice, Alyn
    Sher, Mandel
    Schelfhout, Jonathan
    Muccino, David
    CHEST, 2019, 156 (04) : 1782A - 1783A
  • [39] BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH
    Muccino, D.
    Morice, A.
    Birring, A.
    Mcgarvey, L.
    Dicpinigaitis, P.
    Pavord, I.
    La Rosa, C.
    Urdaneta, E.
    Assaid, C.
    Smith, J.
    CHEST, 2020, 157 (06) : 4A - 4A
  • [40] Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
    Martinez, Fernando J.
    Afzal, Amna Sadaf
    Smith, Jaclyn A.
    Ford, Anthony P.
    Li, Jerry Jing
    Li, Yuping
    Kitt, Michael M.
    PULMONARY THERAPY, 2021, 7 (02) : 471 - 486
12345